Davita Inc vs VanEck Semiconductor ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while VanEck Semiconductor ETF trades at $582.76. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SMH | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | — |
52-Week High | $240.96 | $668.91 |
52-Week Low | $103.87 | $286.43 |
Enterprise Value | $24.44B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
SMH trades at $582.70, up 1.96% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF faces mixed sentiment, with some analysts downgrading to Hold amid competition from income-focused alternatives like CHPY, while others highlight potential from sustained AI spending. Key support lies near $575, with resistance at $588.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include market volatility and concentrated holdings. Institutional activity shows mixed signals, with recent large purchases offset by sales. The ETF's performance hinges on broader tech sector trends and semiconductor cycle dynamics.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →